{"id":"https://openalex.org/W3094539773","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","title":"AB0527 PHARMACOGENETICS AND PHARMACODYNAMICS OF RESPONSE TO APREMILAST IN A PHASE 3 CLINICAL STUDY IN SUBJECTS WITH ACTIVE BEH\u00c7ET'S DISEASE","display_name":"AB0527 PHARMACOGENETICS AND PHARMACODYNAMICS OF RESPONSE TO APREMILAST IN A PHASE 3 CLINICAL STUDY IN SUBJECTS WITH ACTIVE BEH\u00c7ET'S DISEASE","alternate_titles":[],"publication_year":2020,"publication_date":"2020-06-01","ids":{"openalex":"https://openalex.org/W3094539773","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","mag":"3094539773"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2020-eular.1341","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","is_oa":false,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","pdf_url":null,"source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3094539773"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090254983","display_name":"Joseph Maranville","orcid":"https://orcid.org/0000-0002-1688-1573","observed_orcids":["https://orcid.org/0000-0002-1688-1573"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Maranville","raw_affiliation_strings":["Celgene Corporation, Cambridge, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Cambridge, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"I. Medvedeva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Medvedeva","raw_affiliation_strings":["Celgene Corporation, Cambridge, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Cambridge, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012007451","display_name":"Robert Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Yang","raw_affiliation_strings":["Celgene Corporation, Cambridge, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Cambridge, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004750181","display_name":"M. Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Chen","raw_affiliation_strings":["Celgene Corporation, Summit, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, United States of America","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":null,"display_name":"L.R. Fang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L.R. Fang","raw_affiliation_strings":["Celgene Corporation, Cambridge, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Cambridge, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007319347","display_name":"Sonia Collazo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Collazo","raw_affiliation_strings":["Celgene Corporation, Summit, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, United States of America","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062487589","display_name":"Shannon McCue","orcid":"https://orcid.org/0009-0004-0950-5352","observed_orcids":["https://orcid.org/0009-0004-0950-5352"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Mccue","raw_affiliation_strings":["Celgene Corporation, Summit, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, United States of America","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102815745","display_name":"Peter H Schafer","orcid":"https://orcid.org/0000-0002-3880-0850","observed_orcids":["https://orcid.org/0000-0002-3880-0850"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Schafer","raw_affiliation_strings":["Celgene Corporation, Summit, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, United States of America","institution_ids":["https://openalex.org/I4387155837"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":null,"first_page":"1560","last_page":"1561"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11571","display_name":"Sarcoidosis and Beryllium Toxicity Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apremilast","display_name":"apremilast","score":0.8920000195503235},{"id":"https://openalex.org/keywords/behcet-s-disease","display_name":"Beh\u00e7et's disease","score":0.9860000014305115},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.8830000162124634},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8840000033378601},{"id":"https://openalex.org/keywords/phosphodiesterase-4-inhibitors","display_name":"phosphodiesterase-4 inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/oral-ulcers","display_name":"oral ulcers","score":0.9470000267028809},{"id":"https://openalex.org/keywords/hla-b-57-01","display_name":"HLA-B*57:01","score":0.6650000214576721},{"id":"https://openalex.org/keywords/il-10","display_name":"IL-10","score":0.6449999809265137},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.675000011920929},{"id":"https://openalex.org/keywords/il-23","display_name":"IL-23","score":0.7649999856948853},{"id":"https://openalex.org/keywords/interleukin-8","display_name":"interleukin-8","score":0.6570000052452087},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.8309999704360962},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.6729999780654907},{"id":"https://openalex.org/keywords/interferon-lambda","display_name":"interferon lambda","score":0.515999972820282},{"id":"https://openalex.org/keywords/th17-cells","display_name":"Th17 cells","score":0.6990000009536743},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9710000157356262},{"id":"https://openalex.org/keywords/cd3-t-cells","display_name":"CD3+ T cells","score":0.6069999933242798},{"id":"https://openalex.org/keywords/plasma-biomarkers","display_name":"plasma biomarkers","score":0.5329999923706055},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.5799999833106995},{"id":"https://openalex.org/keywords/genetic-polymorphism","display_name":"genetic polymorphism","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.900364875793457},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6615283489227295},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6304745674133301},{"id":"https://openalex.org/C2781427535","wikidata":"https://www.wikidata.org/wiki/Q2858961","display_name":"Apremilast","level":4,"score":0.6029192209243774},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.500499963760376},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.49802374839782715},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.44272661209106445},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4247766435146332},{"id":"https://openalex.org/C31467283","wikidata":"https://www.wikidata.org/wiki/Q912147","display_name":"Genotyping","level":4,"score":0.4230625033378601},{"id":"https://openalex.org/C55775858","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenetics","level":4,"score":0.41161707043647766},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4030640125274658},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3549082279205322},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.30087316036224365},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.2687382102012634},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2551279067993164},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.20719465613365173},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/annrheumdis-2020-eular.1341","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","is_oa":false,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2020-eular.1341","pdf_url":null,"source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3165378283","https://openalex.org/W4283710863","https://openalex.org/W3034615981","https://openalex.org/W3164000502","https://openalex.org/W2984666751","https://openalex.org/W2950913802","https://openalex.org/W2901895918","https://openalex.org/W2807867470","https://openalex.org/W4281791733","https://openalex.org/W3044347807"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3094539773","counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-10-29T00:00:00"}
